General Information |
| Clinical trials phase |
Alternative regulatory mechanism |
| Start date (estimated) |
2023-06-11 |
| End date (estimated) |
2023-12-01 |
| Clinical feature |
| Label |
type 1 diabetes mellitus |
| Link |
http://purl.obolibrary.org/obo/DOID_9744 |
| Description |
A diabetes mellitus that is characterized by destruction of pancreatic beta cells resulting in absent or extremely low insulin production.; Xref MGI.
OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2300072200 |
| Other study identifiers |
|
| Source weblink |
https://www.chictr.org.cn/showproj.html?proj=192835 |
| Public contact |
| Email |
zhongyangshen@vip.sina.com |
| Public email |
zhongyangshen@vip.sina.com |
| First name |
Zhongyang |
| Last name |
Shen |
| Phone |
+86 138 0301 9898 |
| City |
Tianjin |
| Country |
|
|
| Sponsors |
Tianjin First Center Hospital
|
Cells |
| Which differentiated cell type is used |
| Label |
progenitor cell of endocrine pancreas |
| Link |
http://purl.obolibrary.org/obo/CL_0002351 |
| Description |
A progenitor cell that is able to differentiate into the pancreas alpha, beta and delta endocrine cells. This cell type expresses neurogenin-3 and Isl-1. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
3 |
